Therapeutic Effect and Safety of Repaglinide and Gliclazide in the Treatment of Elderly Type 2 Diabetes Mellitus
- VernacularTitle:瑞格列奈与格列齐特治疗老年2型糖尿病的疗效与安全性
- Author:
Wen JIANG
;
Ling YUE
;
Huiling SUN
- Publication Type:Journal Article
- Keywords:
Type 2 diabetes mellitus;
Repaglinide;
Gliclazide;
Efficacy;
Safety
- From:
China Pharmacist
2014;(5):808-810
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical efficacy and safety of repaglinide and gliclazide in the treatment of elderly type 2 di-abetes mellitus (T2DM). Methods:A total of 225 T2DM patients with the age over 60 were enrolled and randomly divided into repa-glinide group (n=112) and gliclazide group (n=113). The repaglinide group was given repaglinide 0. 5~2 mg, po, tid, while the gliclazide group was given gliclazide modified release tablets 30~120 mg, po, qd,both with the treatment course of 12 weeks. The level of FPG, 2h PG, HbAlC, TC and TG and the side effects were observed and the clinical efficacy was compared between the two groups. Results:The level of FPG, 2h PG, HbAlc and TC in the two groups showed significant decrease after the treatment (P<0. 01 or P<0. 05), and the level of 2h PG was decreased more significantly in the repaglinide group (P<0. 05). There were no significant differ-ences in the total effective rate (91. 8% vs 86. 2%), hypoglycemia incidence (4. 5% vs 8. 2%) and ADR incidence (6. 4% vs 10. 1%) in the two groups (P>0. 05). Conclusion:Both repaglinide and gliclazide show safe and reliable efficacy in the treatment of elderly T2DM.
